The role of the extracellular matrix protein SPOCK2 for bone physiology and hematopoiesis
- PMID: 40403823
- DOI: 10.1016/j.bone.2025.117539
The role of the extracellular matrix protein SPOCK2 for bone physiology and hematopoiesis
Abstract
The bone marrow microenvironment (BMM) consists of different cellular and acellular components. These components synergize in regulating the process of hematopoiesis. Various extracellular matrix proteins are found amongst the acellular components. Secreted protein acidic and rich in cysteine (SPARC) is amongst the most abundant glycoproteins in bone. Sparc/osteonectin, cwcv, and Kazal-like domains proteoglycan 2 (SPOCK2) is a member of the SPARC family, and its role in bone metabolism and hematopoiesis has not been investigated. Using female mice deficient for SPOCK2, we assessed the role of SPOCK2 in influencing bone formation, the BMM and hematopoiesis. Using micro-computed tomography we found a significant decrease in trabecular bone volume, bone mineral density and thickness, but increased cortical mineral density in SPOCK2 knockout (KO) versus wildtype (WT) bones. C-terminal telopeptide of type I collagen, a measure of bone resorption, was significantly increased in bone marrow supernatants of SPOCK2 KO mice. In the hematopoietic compartment we found an increase in hematopoietic stem cells, but a decrease of mesenchymal stromal cells and adipocytes in the bone marrow of SPOCK2 KO mice compared to control mice. Megakaryocytes were increased in SPOCK2 KO mice. In summary, deficiency of SPOCK2 leads to several alterations in the BMM. The hematopoietic effects may be due to hematopoietic cell-intrinsic effects in SPOCK2-deficient cells or due to a SPOCK2-deficient niche or both.
Keywords: Bone; Bone marrow microenvironment; Extracellular matrix; Hematopoiesis.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that this work was supported by Merck KGaA. D.S.K. holds patents WO2018046666A1 - “Fibronectin or ILK inhibitors for use in the treatment of leukemia” and WO2020016346A1 - “Periostin compounds for the treatment of haematological complications”. R.K. holds patent WO2018046666A1 - “Fibronectin or ILK inhibitors for use in the treatment of leukemia”.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
